Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Acadia Pharmaceuticals Inc.
About
Acadia Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.
- 501 - 1000
Highlights
Details
- Last Funding Type
- Debt Financing
- Last Funding Money Raised
- $22M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jul 16, 1993
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 7, 2006 | Post-IPO Equity | $20M | 1 | — | — | Detail |
| Jun 20, 2000 | Debt Financing | $22M | 2 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Debt Financing |
Nomura International
|
— | Post-IPO Equity |
Pacific Rim Ventures
|
— | Debt Financing |
